{"id":"94d08de1-6a04-5414-a63b-3748275a3bdd","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:b3-redox-nadk-naad-negative","predicate":"does_not_phosphorylate","statement":"The recombinant human NADK study did not detect phosphorylation of nicotinic acid adenine dinucleotide (NAAD).","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"ec90a5e6-e201-524f-9835-8142c8086912","mechanism_event_label":"Changing the nicotinamide group changes which nucleotide the kinase can use.","subject":{"id":"8605f336-0b29-55bd-ba5c-1e15479d4e07","slug":"nadk","display_name":"NADK","entity_type_key":"protein"},"object":{"id":"4be03515-1913-50d7-a676-dbbb49a0809d","slug":"nicotinic-acid-adenine-dinucleotide","display_name":"Nicotinic acid adenine dinucleotide","entity_type_key":"small_molecule"},"evidence_count":1,"mechanism_event":{"id":"ec90a5e6-e201-524f-9835-8142c8086912","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:b3-redox-nadk-naad-negative-event","event_type":"biochemical_relationship","label":"Changing the nicotinamide group changes which nucleotide the kinase can use.","description":"The recombinant human NADK study did not detect phosphorylation of nicotinic acid adenine dinucleotide (NAAD).","status":"provisional","compartment":null,"participants":[{"entity":{"id":"8605f336-0b29-55bd-ba5c-1e15479d4e07","slug":"nadk","display_name":"NADK","entity_type_key":"protein"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"4be03515-1913-50d7-a676-dbbb49a0809d","slug":"nicotinic-acid-adenine-dinucleotide","display_name":"Nicotinic acid adenine dinucleotide","entity_type_key":"small_molecule"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-redox-sources/nadk-human-2001.abstract.txt\", \"locator\": \"Indexed abstract, substrate specificity\", \"start_char\": 734, \"end_char\": 1005, \"file_sha256\": \"98ea2e14dad1649e591f0c6420828328f84a7fe9e083e24b7379d6b680f11958\", \"text_sha256\": \"e61bb4892b61f0ed3a4b2eda8bc0131424a7854f7bd670fbd1544936b99c4d88\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Recombinant human NADK","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"NAAD compared with NAD","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Scoped experimental observation; no dietary niacin or magnesium deficiency threshold or treatment benefit was tested.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Changing the nicotinamide group changes which nucleotide the kinase can use.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nadk-human-2001] Structural and functional characterization of human NAD kinase. (2001). https://pubmed.ncbi.nlm.nih.gov/11594753/ DOI: 10.1006/bbrc.2001.5735","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Purified enzyme","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ea19dd36-15ab-571c-b455-41d23ac814c7","evidence_kind":"source_excerpt","locator":"Lines 858-869","start_line":858,"end_line":869,"excerpt":"### b3-redox-nadk-naad-negative\nThe recombinant human NADK study did not detect phosphorylation of nicotinic acid adenine dinucleotide (NAAD).\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Changing the nicotinamide group changes which nucleotide the kinase can use.\norganism: Homo sapiens\ntissue_or_cell_type: Purified enzyme\nexperimental_model: Recombinant human NADK\nlimitations: Scoped experimental observation; no dietary niacin or magnesium deficiency threshold or treatment benefit was tested.\nexposure: NAAD compared with NAD\nevidence_span: {\"source_cache\": \"artifacts/niacin-redox-sources/nadk-human-2001.abstract.txt\", \"locator\": \"Indexed abstract, substrate specificity\", \"start_char\": 734, \"end_char\": 1005, \"file_sha256\": \"98ea2e14dad1649e591f0c6420828328f84a7fe9e083e24b7379d6b680f11958\", \"text_sha256\": \"e61bb4892b61f0ed3a4b2eda8bc0131424a7854f7bd670fbd1544936b99c4d88\"}\n[nadk-human-2001] Structural and functional characterization of human NAD kinase. (2001). https://pubmed.ncbi.nlm.nih.gov/11594753/ DOI: 10.1006/bbrc.2001.5735","model_system":"Recombinant human NADK","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nadk-human-2001] Structural and functional characterization of human NAD kinase. (2001). https://pubmed.ncbi.nlm.nih.gov/11594753/ DOI: 10.1006/bbrc.2001.5735","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}